SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Clark WH Jr., Elder DE, Guerry DP IV, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81: 18931904.
  • 2
    Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002; 138: 603608.
  • 3
    Ostmeier H, Fuchs B, Otto F, et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol. 2001; 145: 203209.
  • 4
    Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Below thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer staging. Cancer. 2000; 88: 589595.
  • 5
    Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001; 137: 11691173.
  • 6
    Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995; 75: 478494.
  • 7
    Ribatti D, Ennas MG, Vacca A, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003; 33: 420425.
  • 8
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 9
    Balch CM. Cutaneous melanoma. In: GreeneFL, PageDL, FlemingID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer Verlag, 2002: 209217.
  • 10
    Carlson JA, Slominski A, Linette GP, et al. Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol. 2003; 120(Suppl): 101127.
  • 11
    Cook MG. The significance of inflammation and regression in melanoma. Virchows Arch A Pathol Anat Histopathol. 1992; 420: 113115.
  • 12
    Busam KJ, Antonescu CR, Marghoob AA. Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. Am J Clin Pathol. 2001; 115: 856860.
  • 13
    Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77: 13031310.
  • 14
    Mihm MC Jr., Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996; 74: 4347.
  • 15
    Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002; 4: 504511.
  • 16
    Hakansson A, Gustafsson B, Krysander L, Hakansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996; 74: 670676.
  • 17
    Hakansson A, Gustafsson B, Krysander L, Hakansson L. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res. 1998; 18: 3339.
  • 18
    Hakansson A, Gustafsson B, Krysander L, Hjelmqvist B, Rettrup B, Hakansson L. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer. 2001; 85: 18711877.
  • 19
    Håkansson A, Håkansson L, Gustafsson B. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. Melanoma Res. 2003; 13: 401407.
  • 20
    Qiang L, Yi J, Fu-De C. Melanoma vaccine based on the vector of membrane fusogenic liposomes. Pharmazie. 2004; 59: 263267.
  • 21
    Obata C, Zhang M, Moroi Y, et al. Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions. J Dermatol Sci. 2004; 34: 209219.
  • 22
    Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex Class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res. 2004; 64: 18671874.
  • 23
    Konstadoulakis MM, Vezeridis M, Hatziyianni E, et al. Molecular oncogene markers and their significance in cutaneous malignant melanoma. Ann Surg Oncol. 1998; 5: 253260.
  • 24
    Zehntner S, Townsend W, Parkes J, et al. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology. 1999; 31: 116122.
  • 25
    Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression of thymidine phosphorylase and heme oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J Cancer Res. 2000; 91: 906910.
  • 26
    Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Controversies on the prognostic significance of tumor infiltrating leukocytes in solid human tumors. Anticancer Res. 2000; 20: 17591768.
  • 27
    Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology, 3rd ed. Philadelphia: WB Saunders Company, 1997.
  • 28
    Bernsen MR, Diepstra JH, van Mil P, et al. Presence and localization of T-cell subsets in relation to melanocyte differentiation antigen expression and tumour regression as assessed by immunohistochemistry and molecular analysis of microdissected T cells. J Pathol. 2004; 202: 7079.
  • 29
    Riley PA. Melanoma and the problem of malignancy. Tohoku J Exp Med. 2004; 204: 19.
  • 30
    Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol. 2001; 159: 237243.
  • 31
    Vermi W, Bonecchi R, Facchetti F, et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol. 2003; 200: 255268.
  • 32
    Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003; 33: 10521062.
  • 33
    Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 14141421.
  • 34
    Ladanyi A. Function and prognostic significance of immune cells infiltrating human tumors. Magy Onkol. 2004; 48: 4956.